Advertisement
A replay of each webcast will be made available approximately 24 hoursafter the live presentation and the replay will be archived for 14 days.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical companyfocused on the development and commercialization of novel, proprietaryproducts for the treatment of acute and intermittent conditions. The Company'stechnology, the Staccato(R) system, vaporizes unformulated drug to form acondensation aerosol that allows rapid systemic drug delivery through deeplung inhalation. The drug is quickly absorbed through the lungs into thebloodstream, providing speed of therapeutic onset that is comparable tointravenous administration, but with greater ease, patient comfort andconvenience.
Advertisement
Alexza has five product candidates in clinical development. Alexza's leadprogram, AZ-004 (Staccato loxapine) for the treatment of acute agitation inschizophrenic or bipolar disorder patients, is in Phase 3 testing and theCompany previously announced positive results from the first Phase 3 clinicaltrial. A second Phase 3 clinical trial was initiated in July 2008. AZ-001(Staccato prochlorperazine) for the acute treatment of migraine headaches hascompleted Phase 2 testing, and AZ-104 (Staccato loxapine) for the acutetreatment of migraine headaches is in Phase 2 testing. Product candidates inPhase 1 testing are AZ-003 (Staccato fentanyl) for the treatment ofbreakthrough pain, which is partnered with Endo Pharmaceuticals in NorthAmerica, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. Moreinformation, including this and past press releases from Alexza is availableonline at http://www.alexza.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements thatinvolve significant risks and uncertainties. Any statement describing theCompany's expectations or beliefs is a forward-looking statement, as definedin the Private Securities Litigation Reform Act of 1995, and should beconsidered an at-risk statement. Such statements are subject to certain risksand uncertainties, particularly those inherent in the process of developingand commercializing drugs. The Company's forward-looking statements alsoinvolve assumptions that, if they prove incorrect, would cause its results todiffer materially from those expressed or implied by such forward-lookingstatements. These and other risks concerning Alexza's business are describedin additional detail in the Company's Annual Report on Form 10-K for the yearended December 31, 2007, and the Company's other Periodic and Current Reportsfiled with the Securities and Exchange Commission. Forward-looking statementscontained in this announcement are made as of this date, and the Companyundertakes no obligation to publicly update any forward-looking statement,whether as a result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.
